İlaca bağlı tiroid bozuklukları

Year 2015, Volume: 5 Issue: 3, 191 - 196, 01.10.2015

Müge Kökümer Ahmet Özer Şehirli

Abstract

İlaçlar hastalıkları tedavi ederken bazı durumlarda çeşitli yan etkiler gösterirler ve bu yan etkiler yeni hastalıkların gelişmesine sebep olabilir. Bu ilaca bağlı hastalıklardan biri de ilaç kaynaklı tiroid bozukluklarıdır. Yapılan çalışmalarla ilaca bağlı tiroid bozukluklarına neden olan pek çok ilaç belirlenmiştir. Özellikle amiodaron, lityum ve interferon gibi ilaçlarla çeşitli yan etkiler görülmektedir. Bu ilaçlarla görülen yan etkiler önemsiz olduğu gibi kayda değer sonuçlara yol açabilen seviyelerde olabilir. İlaçlar tiroid hormonu sentezi, salgılanması, fonksiyonu ve düzenlenmesini etkilemek gibi çeşitli mekanizmalarla bu yan etkilere sebep olmaktadırlar. Yan etkiler görüldüğünde ilacın dozu azaltılabilir, kullanımına son verilebilir veya başka bir ilaç tedaviye eklenebilir. Özellikle risk altındaki hastalar ilaç kaynaklı tiroid bozukluklarının belirti ve semptomları konusunda eğitilmelidirler ve bu belirti ve semptomlarla karşılaşmaları durumunda kendilerine hastaneye başvurmaları gerektiği söylenmelidir.

Keywords

İlaç, hipertiroidizm, hipotiroidizm

Drug-induced thyroid disorders

Abstract

Drugs cure the diseases, but sometimes adverse effects occur and these adverse effects may cause new diseases. Drug-induced diseases include drug-induced thyroid disorders. The studies show that there are few agents implicated in drug-induced thyroid disorders, especially amiodarone, lithium and interferons, and that these agents can lead to significant consequences or these effects may not be important. Drugs induce adverse effects via various mechanisms. They may affect thyroid hormone synthesis, release, function or regulation. When adverse effects occur, minimizing or discontinuation of the suspected drug or addition of a new drug may be required. Particularly in patients at risk should be educated on signs and symptoms of drug-induced thyroid disorders. If they experience these signs and symptoms they should be advised to admit to a hospital.

Keywords

Drug, hyperthyroidism, hypothyroidism

References

• Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients—a meta-analysis of prospective studies. JAMA. 1998; 279: 1200-1205.
• Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009; 23: 793-800.
• Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest. 1969;48: 2096–103.
• Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, Fox N, Huyghe MR, Kean Y, Reich SD, Hong WK. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2001; 19: 2626-2637.
• Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003; 21: 999-1006.
• Sherman SI, Gopal J, Haugen BR, Chiu AC, Whaley K, Nowlakha P, Duvic M. Central hypothyroidism associated with retinoid x receptor selective ligands. New Eng J Med. 1999; 340: 1075-1079.
• Liu S, Ogilvie KM, Klausing K, Lawson MA, Jolley D, Li D, Bilakovics J, Pascual B, Hein N, Urcan M, Leibowitz MD. Mechanism of selective retinoid x receptor agonist-induced hypothyroidism in the rat. Endocrinology. 2002; 143: 2880-2885.
• Golden WM, Weber KB, Hernandez TL, Sherman SI, Woodmansee WW, Haugen BR. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. J Clin Endocrinol Metab. 2007; 92: 124-130.
• Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Res. 2013; 6: 3-7.
• Ohzeki T, Hanaki K, Motozumi H, Ohtahara H, Ishitani N, Urashima H, Tsukuda T, Shiraki K, Sasaki S, Nakamura H, et al. Efficacy of bromocriptine administration for selective pituitary resistance to thyroid hormone. Horm Res. 1993; 39(5-6): 229-234.
• Morley JE. Neuroendocrine control of thyrotropin secretion. Endocr Rev. 1981; 2(4): 396-436.
• Samuels MH, Henry P, Ridgway EC. Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. J Clin Endocrinol Metab. 1992; 74(1): 217-222.
• Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev. 1995;16(4):427-42.
• Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, Facchetti M, Beck-Peccoz P. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol (Oxf). 2005;62(2):176-81.
• Hofland LJ, Lamberts SW. Somatostatin receptors in pituitary function, diagnosis and therapy. Front Horm Res. 2004;32:235-52.
• Samuels MH, Henry P, Ridgway EC. Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. J Clin Endocrinol Metab. 1992; 74(1): 217-222.
• Lightman SL, Fox P, Dunne MJ. The effect of SMS 201-995, a long- acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. Scand J Gastroenterol Suppl. 1986; 119: 84-95.
• Hindmarsh PC, Pringle PJ, Stanhope R, Brook CG. The effect of a continuous infusion of a somatostatin analogue (octreotide) for two years on growth hormone secretion and height prediction in tall children. Clin Endocrinol (Oxf). 1995; 42(5): 509-515.
• Colao A, Merola B, Ferone D, Marzullo P, Cerbone G, Longobardi S, Di Somma C, Lombardi G. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non- functioning pituitary adenomas. Eur J Endocrinol. 1995; 133(2): 189- 194.
• Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem. 1989; 35: 1882-1887.
• Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Braverman L, Pinchera A. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res. 1987; 26(1-4): 158-171.
• Newman CM, Price A, Davies DW, Gray TA, Weetman AP. Amiodarone and the thyroid: A practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998;79: 121-127.
• Chen JT, Dong BJ, Pucino F, Calis KA. Thyroid disorder. In: Tisdale JE, Miller DA, eds. Drug-induced diseases. American Society of Health- System Pharmacists, Bethesda: 2010. p.586-604.
• Geng J, Lu W, Hu T, Tao S, Zhang H, Chen J, Bu Y, Ma S, Wang B. Subclinical hyperthyroidism increases risk of coronary heart disease events in type 2 diabetes mellitus. Endocrine. 2014; 9.
• Gorka J, Taylor-Gjevre RM, Arnason T. Metabolic and clinical consequences of hyperthyroidism on bone density. Int J Endocrinol. 2013; 2013: 1-11.
• Chaudhari D, Gangadharan V, Forrest T. Heart failure presenting as myxedema coma: case report and review article. Tenn Med. 2014; 107(2): 39-41.
• Trip MD, Düren DR, Wiersinga WM. Two cases of amiodarone-induced thyrotoxicosis successfully treated with a short course of antithyroid drugs while amiodarone was continued. Br Heart J. 1994; 72: 266-268.
• Chalasani S, Benson KA. Lithium-induced thyrotoxicosis in a patient with treatment-resistant bipolar type I affective disorder. Med J Aust. 2014; 201(9): 541-542.